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CHARACTERIZATION OF THE PHARMACOLOGICAL EFFECTS OF CARDIAC 
GLYCOSIDES ON LUNG EPITHELIAL CELLS 
 
by Hosam Abdelmonaim Elbaz 
         Lung diseases (excluding cancer) account for 9% of all disease related mortalities 
while lung cancer accounts for 30% of cancer related mortalities. Therapeutic maneuvers, 
as surgery are usually unfeasible given the extreme vitality of the lung. Developing novel 
therapeutic alternatives for lung cancer requires a thorough understanding on the lung 
epithelial cell behavior following exposure to drugs. The goal of this dissertation was to 
examine how molecular and cellular characteristics, such as morphology and cell viability, 
of lung cancer cells will be altered upon exposure to digitoxin, a cardiac glycosides (CGs) 
and a digitoxin synthetic analog. CGs are a large family of chemical compounds found in 
several plants and animal species and have been applied for treating congestive heart 
failure, cardiac arrhythmias, and atrial fibrillation.  The study was conducted on non-small 
cell lung cancer (NSCLC) cells using several techniques such as different cell proliferation 





My Parents Abdelmonaim Elbaz and Ibtesam Abdelhameed 
My wife Omayma Alshaarawy 
My daughter Hannah and son Omar 
My brother Moataz Elbaz and sister Gehan Elbaz 
 iv 
ACKNOWLEDGMENTS 
 The process of conducting research is unfeasible without the personal and 
practical support of numerous people. I owe debt of gratitude to all those people who 
have made this dissertation possible and because of whom my graduate experience 
has been an enriching and rewarding one. 
 I am deeply indebted to my esteemed advisor, Dr. Cerasela Zoica Dinu for her 
encouragement, support, patience and guidance. She is an excellent scientist and 
mentor, and one of the most efficient persons I have ever encountered. I believe that I 
am quite fortunate to have had the opportunity to work with her. I also want to thank my 
co-advisor Dr. Yon Rojanasakul for he has taught me a lot in scientific research, and in 
life. I am eternally grateful to him for his assistance, guidance, and giving me the 
opportunity to perform laboratory experiments. I was lucky to have the opportunity to 
work with both distinguished investigators. Their mentorship provided a well-rounded 
experience, and they encouraged me to grow as an experimentalist and an independent 
thinker. 
 I would also like to thank my committee members, Dr. Patrick Callery, Dr. Linda 
Vona-Davis, and Dr. Rae Matsumoto for their insightful comments and valuable 
suggestions that helped in my research. I want to express my deep appreciation and 
gratitude to Dr. Todd Stueckle for advising me on my research. I thank Dr. George 
O’Doherty for his collaboration that contributed an important part of my research project.   
 I would also like to thank the faculty, staff and graduate students of the department 
of Basic Pharmaceutical Sciences for their help and discussion. I want to acknowledge 
 v 
past and current members of Dr. Dinu’s lab and Dr. Rojanasakul’s lab for being 
excellent colleagues. I am also grateful to my colleagues at National Institute for 
Occupational Safety and Health for their assistance and encouragement.  
 My family has helped me stay sane through these difficult years. Their support and 
care helped me overcome setbacks and stay focused on my graduate study. I greatly 
value their kinship and I deeply appreciate their belief in me.
 vi 
TABLE OF CONTENTS 
ABSTRACT……………………………………………………………………………………. ii 
DEDICATION        ……………………………………………………………………………...iii 
ACKNOWLEDGMENTS……………………………………………………………………….iv 
TABLE OF CONTENTS………………………………………………………………………..vi 
LIST OF FIGURES……………………………………………………………………………..vii 
LIST OF TABLES……………………………………………………………………………….ix 
LIST OF SYMBOLS / NOMENCLATURE…………………………………………………….x 
INTRODUCTION…………………………………………………………………………………1 
CHAPTER 1: DIGITOXIN, A CARDIAC GLYCOSIDE WITH THE POTENTIAL TO  
PROVIDE A NEW HOPE FOR CANCER THERAPY…………………...............................7 
CHAPTER 2: DIGITOXIN AND A SYNTHETIC MONOSACCHARIDE ANALOG INHIBIT 
CELL VIABILITY IN LUNG CANCER CELLS………………………………………………36  





LIST OF FIGURES 
CHAPTER 1: DIGITOXIN, A CARDIAC GLYCOSIDE WITH THE POTENTIAL  
TO PROVIDE A NEW HOPE FOR CANCER THERAPY 
SCHEME 1: Structural characteristics of CGs………………………………………………..9 
SCHEME 2: The effects of digitoxin on the Na+/K+ATPase at micromolar and at 
nanomolar concentrations……………………………………………………………………...14 
SCHEME 3: The structure of the novel digitoxin analogs.……………………….…………15 
FIGURE 1: Digitoxin manipulates the Na+/K+ATPase signalosome and inhibits the 
transcriptional activity of AP-1 and NF-ΚB. ……………………………...…………………..19 
 
CHAPTER 2: DIGITOXIN AND A SYNTHETIC MONOSACCHARIDE ANALOG INHIBIT 
CELL VIABILITY IN LUNG CANCER CELLS 
FIGURE 1: Digitoxin and D6-MA inhibit NCI-H460 cell viability in a dose dependent 
manner.………………………………………………………………………………..…………46 
FIGURE 2: Digitoxin and D6-MA induce NCI-H460 cell apoptosis in a dose dependent 
manner…………………………………………………………...………………………………47 
FIGURE 3: The apoptotic effect of digitoxin and D6-MA is selective to non-small cell lung 
cancer cells……………………………………………………………………………………...48 
FIGURE 4: Western blot analysis show changes in caspase9, 8, and 3………………….50 
FIGURE 5: Western blot analysis shows changes in cytochrome c expression………….51 
FIGURE 6: Digitoxin and D6-MA induce G2/M arrest in NCI-H460 cells.…………………52 
 
 viii 
FIGURE 7: Western blot analysis show decreased expression of cyclinB1, cdc2, and 
survivin…………………………………………………………………………….....................54 
FIGURE 8: Western blot analysis show decreased expression of p53, p21, and p27
……………………………………………………………………………………………………56 






LIST OF TABLES 
CHAPTER 1: DIGITOXIN, A CARDIAC GLYCOSIDE WITH THE POTENTIAL TO 
PROVIDE A NEW HOPE FOR CANCER THERAPY 
 
TABLE 1:  
A summary of the most studied CGs and their anticancer activity…………………………11  
 
 x 
LIST OF SYMBOLS / NOMENCLATURE 
 
1. AP-1:  Activator protein 1 
2. Cdc2:  cell division cycle 2 
3. Cdk1:  cyclin dependent kinase 1 
4. Cdk4:  cyclin dependent kinase 4 
5. Chk1:  checkpoint kinase protein 1 
6. Chk2:  checkpoint kinase protein 2 
7. D6-MA:  digitoxin-α-L-monosaccharide analog 
8. MAPK:  mitogen activated protein kinase 
9. Na+/K+ATPase:  sodium potassium ATPase 
10. Na+/Ca2+ exchanger:  sodium calcium exchanger 
11. NF-κB:  nuclear factor kappa beta  
12. NSCLC: non-small cell lung cancer 
13. PI3K:  phosphatidal inositol-3 kinase 
14. PKC:  protein kinase C 
15. PLC:  phospholipase C  
 
 1 
I N T R O D U C T I O N  
          Lungs are extremely vital organs in the living mammalian body. Significantly 
undermined lung functions are correlated with acute morbidity and mortality. According to 
the disease statistics conducted by the National Heart Lung and Blood Institute (NHLBI) 
in 2006, excluding lung cancer, death causes due to lung diseases comprise 9%, while 
lung cancer accounted for 12.5% of all new cancer cases and 29% of all cancer related 
deaths, ranking second in new cancer cases and first in cancer related mortality [1].  
          Lung cancer is primarily due to exposure to external or environmental factors, such 
as smoking, gas radon, and asbestos [2, 3]. Lung cancer has significantly poor prognosis, 
with a median survival rate of 15% over a 5-year period [4]. That is in part due to the wide 
signaling array that enables lung cancer cells to escape cell death by conventional 
chemotherapy [5, 6], and the limited therapeutic approaches that are able to effectively 
manage lung cancer [4, 7, 8]. Radiotherapy and/or surgical intervention are usually 
unfeasible for the majority of lung cancer cases, leaving chemotherapy as one of the few 
adequate options [4, 7, 8]. Therefore, developing novel therapeutic strategies for lung 
cancer is of critical need.   
Records dating back to the eighth century showed the potential applicability of 
cardiac glycosides for managing malignant diseases [9, 10]. Later, about two hundred 
years ago cardiac glycosides were developed as cardiotonic agents [10-12]. Studies on 
the anti-neoplastic potential for cardiac glycosides continued in the sixties, however they 
were abandoned due to potential cardiotoxicity of the cardiac glycosides, and lack of 
representative biological models [10, 13, 14]. Yet, in the late seventies, epidemiological 
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studies conducted on breast cancer patients maintained on digitalis (a cardiac glycoside) 
therapy for cardiac conditions showed that these patients had significantly lower chances 
for developing malignant conditions, and significantly better prognosis, compared to 
patients never exposed to digitoxin therapy [15-18].  
Laboratory research has also showed that cardiac glycosides possess a promising 
anti-neoplastic potential against few types of cancer [10, 19-25]. However, the 
concentrations employed in these studies (0.1 µM – 10 µM) [10, 26, 27] significantly 
exceeded those indicated in the epidemiological reports (15 nM – 40 nM) [15, 17, 28-30]. 
This means that the mechanism by which cardiac glycosides mediate their anti-neoplastic 
effect at or below therapeutic doses (15 nM – 40 nM) is still unknown. 
The work cited above provides convincing evidence that cardiac glycosides can be 
developed into potential therapeutic strategies to improve the quality of life of persons 
affected by lung cancer. However, because cardiac glycosides are infamous for 
cardiotoxicity, they are not actively studied as anticancer therapeutic alternatives [10, 26, 
27, 31]. A potential approach to circumvent their cardiotoxicity is to manipulate their 
chemical structure.  
The long-term goal of this research was to develop cardiac glycosides as novel 
therapeutic alternatives for lung cancer. In pursuit of this goal, the short-term goal was to 
examine the effects of digitoxin and a synthetic analog to circumvent digitoxin’s 
cardiotoxicity on NCI-H460 cells, a cell model for non-small cell lung cancer (NSCLC) 
cells. Understanding how digitoxin and synthetic analogue inhibit lung cancer cell viability 
would provide a broader perspective on how those chemical agents mediate their anti-
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neoplastic effects. Such understanding would also generate a myriad of new 
opportunities for developing novel anti-neoplastic drugs for lung cancer. 
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C H A P T E R  1  
DIGITOXIN, A CARDIAC GLYCOSIDE WITH THE POTENTIAL TO PROVIDE A NEW 
HOPE FOR CANCER THERAPY 
 
ABSTRACT 
          A growing body of evidence indicates that digitoxin cardiac glycoside is a promising 
anticancer drug when used at therapeutic concentrations. Digitoxin has a prolonged half-
life and a well-established clinical profile. New scientific avenues showed that 
manipulating the chemical structure of the saccharide moiety of the digitoxin leads to 
synthetic analogs with increased cytotoxic activity.  However, the anticancer mechanism 
of digitoxin or synthetic analogs is still subject to study while concerns about digitoxin’s 
cardiotoxicity precludes its clinical application in cancer therapeutics. This chapter 
focuses on digitoxin and a digitoxin analog, and their cytotoxic selectivity against cancer 
cells. Moreover, a new perspective on the pharmacological aspects of digitoxin and its 




Cardiac glycosides (CGs) are a large family of chemical compounds found in 
several plants and animal species [1]. Plants containing CGs were used for more than 
1500 years as diuretics, emetics, abortifacients, antineoplastics, and heart tonics [2]. In 
18th century, English physician and scientist William Withering discovered that a patient 
with congestive heart failure, “dropsy”, improved after administering foxglove extract 
 
 8 
(Digitalis purpurea L.) [3]. Since then, many CGs have been isolated and their 
pharmacological effects have been tested; subsequently, CGs were used for treating 
congestive heart failure, cardiac arrhythmias, and atrial fibrillation [4, 5].  
Generally, CGs share a common structural motif with a steroidal nucleus, a sugar 
moiety at position 3 (C3), and a lactone moiety at position 17 (C17) [1]. SCHEME 1 
shows the common structural motif of CGs. The steroidal nucleus is the core structure of 
CG and is considered to be the active pharmacophoric moiety [6]. CGs also show an A/B 
and C/D cis-conformation that is different from mineralocorticoids, glycocorticoids, or sex 
hormones known to show trans-confirmation [6]. The presence of sugars at position 3 on 
the steroid ring significantly modifies the pharmacological profile of each glycoside [7, 8]. 
Free aglycones, for instance, show faster and less complex absorption and metabolism 
compared to their glycosylated counterparts [7]. Additionally, the type of the sugar 
attached to the steroidal nucleus changes the potency of the CG’s compound [8, 9].  
It is well established that CGs inhibit Na+/K+ATPase and increases intracellular 
sodium ions [10]. The Na+/K+ATPase is a P-type pump that actively transports potassium 
ions inside and sodium ions outside cells in a 2:3 stoichiometry [11]. Such activity keeps 
intracellular sodium levels low, thus initiating and sustaining adequate electrochemical 
gradient across the plasma membrane [11]. Appropriate electrochemical gradient is 
essential for vital cellular processes such as ion homeostasis, neuronal communication, 
and apoptosis [10, 12]. To maintain ion homeostasis after Na+/K+ATPase inhibition by 
CGs, the cells have to restore intracellular sodium concentration to their basal levels by 
stimulating the Na+/Ca2+ exchange pump to extrude sodium ions out of the cell and 
introduce calcium ions inside the cell [10]. This activity increases intracellular calcium ions 
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and results in increased cellular phenomena such as calcium dependent signaling and 
myocardial contractility [5].  
 
SCHEME 1: Structural characteristics of CGs. The common structural motif of a CG 
molecule is characterized by a steroidal nucleus, a lactone moiety at C17, and a 
saccharide moiety at C3 linked to the steroidal nucleus by a glycosidic linkage. 
 
CARDIAC GLYCOSIDES AND THEIR ANTICANCER POTENTIAL 
A growing body of evidence suggests significant anticancer effects mediated by 
CGs. For instance, in the 8th century, CG plant extracts were used for treating malignant 
conditions [13]. An ancient Chinese remedy that employs an extract of Bufo bufo toad 
secretions contains several CGs and is still being used today for managing cancerous 
conditions [14-16]. Investigations in using CG’s as anticancer drugs intensified in 1960s 
[17, 18]. Shiratori et al., (1967) examined CGs cytotoxicity on rodent cancer models and 
found inhibition of in vitro proliferation at concentrations that are relatively toxic to humans 
(0.1 µM - 10 µM).  
A series of landmark epidemiological studies by Stenkvist et al. compared breast 
cancer tissue sample from women maintained on digitalis (a CG) for cardiac conditions to 
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tissue samples from control patients. This research found that women on digitalis therapy 
developed more benign forms of breast tumors when compared to control patients [19-
22]. Additionally, patients on digitalis treatment showed 9.6-times lower cancer recurrence 
rate compared to control patients after 5 years from mastectomy [21]. In 1984, Goldin and 
colleagues examined 127 cancer patients treated with digitalis. While patients in the 
control group had 21 cancer-related deaths, only one patient died in the digitalis group 
[23]. 20 years later using follow-up data, Stenkvist et al. found that those patients on 
digitalis treatment showed significantly lower mortality rate compared to the control group 
[22]. Given the promising epidemiological results and the emergence of human cancer 
cell lines, several studies investigated the cytotoxic effect of different cardiac glycosides 
on human cancer cells.  
Examples of the cardiac glycosides of plant or animal origins that showed 







TABLE 1: A summary of the most studied CGs and their anticancer activity. 
Compound Structure and Natural Origin Susceptible cancer types IC50 (µM) References 
Bufalin 
 
Bufo bufo gargarizans 
• Prostate cancer (PC3, 
DU145, and LNCaP cells) 
• Leukemia (THP1, U937, and 
MOLT-3 cells) 




Bufo bufo gargarizans 
• Prostate cancer (PC3, 
DU145, and LNCaP cells) 
0.1– 10 [39, 40, 45, 
46, 48, 49] 
Digitoxin 
 
Digitalis purpurea and Digitalis 
lanata, (Scrophulariaceae) 
• Prostate cancer (PC3, 
DU145, and LNCaP cells) 
• Breast cancer (MCF-7 cells) 
• Renal adenocarcinoma (TK-
10 cells) 
• Melanoma (UACC-62 cells) 
• Leukemia (K-562 cells) 
• Lung (A549 cells, and NCI-
H460 cells) 
0.01–10 [35, 50-61] 
Digoxin 
 
Digitalis purpurea and Digitalis 
lanata, (Scrophulariaceae) 
• Prostate cancer (PC3, 
DU145, and LNCaP cells) 
• Cervical cancer (Hela cells) 
• Lung (A549 cells, and NCI-
H460 cells) 






• Prostate cancer (PC3, 
DU145, LNCaP) 
• Leukemia (U-937, and HL-60 
cells) 
• Breast cancer (MCF-7) 
• Lung 
• Malignant Fibroblast (VA-13) 
• Liver carcinoma (HepG2 
cells) 
• Pancreatic cancer (PANC-1 
cells) 






• Prostate cancer (PC3, 
DU145, LNCaP) 
• Breast cancer (MDA-MB-
435scells) 
• Lung (NCI-H460 cells) 
0.1– 10 [10, 50, 51, 





Urginea Maritime, (Liliaceae) 






[50, 51, 53, 





DIGITOXIN, A WELL ESTABLISHED CARDIAC GLYCOSIDE 
Digitoxin is one of the few CGs that has been extensively studied, and has a well-
established clinical profile [24, 25]. Digitoxin is a cardiotonic drug with a narrow 
therapeutic window; thus, toxicity is a persistent concern whenever digitoxin is considered 
for therapy [26]. Cardiotoxicity is frequently encountered as the most significant toxicity 
following digitoxin’s clinical administration [27, 28]. However, digitoxin is perhaps the most 
promising of the CGs since it showed significant anticancer effect against several types of 
cancer including lung cancer, pancreatic cancer, leukemia, and breast cancer, all at 
therapeutic concentrations (see TABLE 1) [18, 25, 29-31]. Moreover, digitoxin has a 
prolonged half-life [26], which can potentially contribute to a less toxic and more stable 
pharmacokinetic profile in the digitoxin-treated cancer patients. Such advantages qualify 
digitoxin for further laboratory investigations and clinical trials. However, to justify the 
anticancer clinical application of digitoxin, its anticancer mechanism is ought to be clearly 
understood. Also, with the persistent concern about digitoxin’s cardiotoxicity, further 
studies are required to clarify the cytotoxic mechanism of digitoxin in cancer cells.   
 
DIGITOXIN AND ITS ANTICANCER MECHANISM 
To understand its anticancer mechanisms, initial research focused on the ability of 
digitoxin to inhibit the Na+/K+ATPase pump at concentrations between 0.5 µM – 5 µM [5, 
10-12], [32]. Such inhibition can result in increased intracellular calcium via increased 
Na+/Ca2+ pump activity and subsequently induce apoptosis in cancer cells [33-35]. 
SCHEME 2A shows how inhibiting the Na+/K+ATPase pump will cause accumulation of 
intracellular sodium, thus perturbation of cellular ion homeostasis [5, 10-12]. For the cells 
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to restore ion homeostasis, the Na+/Ca2+ exchanger need to be activated to export excess 
sodium to the extracellular space while importing calcium, which in turn causes 
accumulation of intracellular calcium that mediate events as myocardial contractility, 
cytoskeleton remodeling, and apoptosis [5, 10-12]. Interestingly, however, 
epidemiological studies showed that digitoxin inhibits cancer cell viability at nanomolar 
concentrations (10 nM - 100 nM) [18, 30, 31, 36]. This suggests that digitoxin exhibits a 
different mechanism for its anticancer effect than the one initially proposed.  
 
 
SCHEME 2: The effects of digitoxin on the Na+/K+ATPase at micromolar and at 
nanomolar concentrations respectively. (A) Old theory summarizes the effect of digitoxin 
at 0.5 µM - 5µM concentrations. (B) New theory summarizes digitoxin’s effect at 0.01 µM 
- 0.1µM concentrations. 
 
In 2003, Xie and colleagues suggested that the signaling characteristics of 
Na+/K+ATPase are distinct from the ion pumping activity [37]. It was shown that 
Na+/K+ATPase signalosome is a multiple-protein signaling complex of 3 alpha (α) 
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subunits and 2 beta (β) subunits that controls cellular activities like apoptosis [38], cell 
proliferation [39], cell motility [40], and tight junctions [41]. Subsequently, it was proposed 
that digitoxin at nanomolar concentrations manipulates the Na+/K+ATPase signalosome to 
transmit intracellular signals. SCHEME 2B summarizes the intracellular effects of digitoxin 
upon binding to Na+/K+ATPase at concentrations between (10 nM - 100 nM). Upon 
binding, digitoxin manipulates the Na+/K+ATPase protein complex activating the 
associated downstream signaling pathways, i.e. activation of several signaling cascades 
such as as phospholipase C (PLC) signaling, mitogen-activated protein kinase (MAPK) 
signaling, Phosphatidylinositol-3-Kinase (PI3K) signaling and Src kinase signaling.  
The signaling cascades that are stimulated upon the interaction of digitoxin with 
Na+/K+ATPase have mixed functions. For example, the MAPK signaling is mainly a 
proliferative and a pro-survival signaling, that can also be complemented by pro-apoptotic 
signaling capability [42-48]. Src kinase signaling is a non-receptor tyrosine kinase that 
exhibits pro-survival as well as pro-apoptotic functions [49-57]. Therefore, digitoxin’s 
ability to manipulate the signaling exploited downstream Na+/K+ATPase signalosome is 
very complex. Such complexity together with the digitoxin’s narrow therapeutic window 
and its know characteristic cardiotoxicity [1, 2, 18, 58], led to a slow progress in 
developing digitoxin as anticancer drugs. 
 
DESIGNING DIGITOXIN ANALOGS AS EFFECTIVE ANTICANCER DRUGS 
Early on it was suggested that a potential approach to circumvent digitoxin’s 
cardiotoxicity is to design synthetic analogs that are either more effective or less toxic 
than digitoxin when used as anticancer drugs [8, 59]. Such analogs were designed by 
 
 15 
structural modification of digitoxin’s chemical entity. For example, using digitoxin as a 
model, Langenhan and colleagues developed MeON-neoglycosylation, a chemoselective 
method for glycorandomization that employs modifying the glycosidic bond that links the 
saccharide moiety to the CG core steroidal nucleus of digitoxin [59].  
 
 
SCHEME 3: The structures of novel digitoxin analogs. (A) The common structural motif of 
a neoglycoside molecule developed by Langenhan and colleagues and characterized by 
a tertiary amine bond linking the saccharide moiety to the steroidal nucleus.  (B) The 
common structural motif of a digitoxin O-saccharide molecule developed by O’Doherty 
and colleagues is characterized by an ether bond that links the saccharide moiety to the 
steroidal nucleus. 
 
In 2008, Zhou and O’Doherty developed another method for modifying the 
glycosidic linkage of digitoxin using palladium-catalyzed glycosylation [60, 61]. 
O’Doherty’s analogs are characterized by an ether linkage between the saccharide 
moiety and the steroidal nucleus. As result, novel synthetic digitoxin O-glycoside analogs 
were also synthesized [9, 60, 61]. SCHEME 3 shows the core structures of digitoxin 
analogs synthesized by Langenhan and colleagues, and O’Doherty and colleagues 
respectively. 
The differential potency and cytotoxic selectivity of digitoxin MeON-Neoglycosides 
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and digitoxin O-glycosides respectively was tested against different cancer cell lines. For 
instance, Iyer and colleagues compared a library of different digitoxin MeON-
Neoglycosides and digitoxin O-glycosides in a panel of 60 different cancer cell lines [9]. 
They showed that O-glycosides are more potent anticancer agents when compared to 
MeON-Neoglycosides, in a variety of cancer cell lines from leukemia, to lung, pancreatic 
and breast cancer cells. Additionally, the authors also showed that analog potency 
depends on the sugar moiety with the monosaccharide of digitoxin being more potent 
than the disaccharide and the trisaccharide analog respectively.  
Wang and colleagues tested artificial O-monosaccharide analogs against a panel 
of 60 different cancer cell lines [62-64]. Authors identified three digitoxin monosaccharide 
analogs that showed significantly greater cytotoxic potential against non-small cell lung 
cancer (NSCLC) cells [62-64]. The most promising of these analogs, D6-MA, was 
subsequently chosen by Elbaz and colleagues for further mechanistic studies in order to 
unravel its anticancer mechanism [36].  
 
ANTICANCER MECHANISM AND SELECTIVITY OF DIGITOXIN AND D6-MA 
Elbaz and colleagues showed that the D6-MA analog was 4-5 fold more potent 
than digitoxin in inhibiting cell proliferation, inducing cell cycle arrest and apoptosis in 
NSCLC cells [36]. Authors also showed that digitoxin and D6-MA exhibited significantly 
greater cytotoxicity against NSCLC, when compared to both primary and non-tumorigenic 
lung epithelial lines being tested. The selective cytotoxicity in lung cancer cells induced 
G2/M phase arrest and apoptosis [36]. Moreover, digitoxin and D6-MA inhibited the 
expression of p53, cdc2, cyclinB1, survivin, and Chk1/2.  
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          In order to explain the observed anticancer mechanism, we now postulate that 
digitoxin and D6-MA manipulate several transcriptional regulatory cascades via 
Na+/K+ATPase signalosome [37, 65-72]. Our suggested mechanism to mediate the 
observed selective cytotoxic effect leads to a reduction in the expression of cell cycle 
regulatory proteins that are specifically over expressed in cancer cells when compared to 
normal cells. FIGURE 1 illustrates how digitoxin manipulates gene expression of these 
cancer specific proteins.  
Our assumption is based on previous studies that showed that digitoxin potentially 
inhibits AP-1 signaling and NF-κB signaling through manipulating the Na+/K+ATPase 
signalosome [68, 73-79]. AP-1 is a transcriptional factor that promotes the expression of 
cell cycle regulatory proteins, such as cdc2 and cyclinB1 [80-82]. Several studies showed 
that cyclinB1 is essential for cell viability [83, 84]. CyclinB1 and cdc2 are specifically 
overexpressed in cancer cells [85-90], and complex with each other prior to mitosis. They 
catalyze chromatin condensation as well as nuclear envelope breakdown during mitosis 
[91, 92]. cyclinB1/cdc2 complex performs a rate limiting function in G2/M phase transition 
and protects mitotic cells from apoptosis by activating survivin. Survivin is a vital cell cycle 
regulatory protein that is specifically overexpressed in different cancer types [93-98]. 
Survivin controls progression through mitosis by promoting the chromosomal passenger 
complex, and regulating microtubule dynamics [99-102]. Additionally, survivin regulates 
the mitotic spindle checkpoint [103-106]. Several studies pointed to survivin down-
regulation as being a biomarker for mitotic catastrophe [107-109].  
Additionally, NF-κB transcriptional factor regulates the expression of cell cycle 
regulatory proteins such as survivin [110].  Thus, by inhibiting both AP-1 and NF-κB 
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signaling, digitoxin and D6-MA potentially inhibit the expression of cdc2, cyclinB1, 
survivin, and Chk1/2 as shown in SCHEMES 2 and FIGURE 1. Moreover, the association 
of cyclinB1/cdc2 complex with survivin indicates that the complex is crucial for G2/M 
phase transition and cell viability, and inhibiting its expression by both digitoxin and D6-
MA could potentially explain the selective cytotoxicity of these compounds towards 
cancer cells.  
Since inhibiting Chk1/2 typically elicits checkpoint abrogation, uncontrolled cell 
cycle progression and abolished cell viability [111-113], a potential alternative mechanism 
by which digitoxin and D6-MA inhibit cell viability can be their ability to cause checkpoint 
abrogation.  It is quite unclear, though, how digitoxin and D6-MA inhibit checkpoint kinase 
proteins in cancer cells. Distinguishing between CGs-induced cell cycle arrest and/or 
checkpoint abrogation will further enhance our understanding of how CGs such as 
digitoxin and analog leads to anti-proliferative/cell death effect. 
 
CONCLUSIONS AND OUTLOOK 
Digitoxin and D6-MA strongly modulate cell cycle machinery through the 
Na+/K+ATPase signalosome in a manner that significantly undermines cell viability 
(FIGURE 1). However several questions remain unanswered regarding their mechanistic 





FIGURE 1: Digitoxin manipulates the Na+/K+ATPase signalosome and inhibits the 
transcriptional activity of AP-1 and NF-κB, which mediate the expression of cancer 
specific cycle regulatory genes as cyclin B1, cdc2, Chk1, Chk2, and survivin.  
 
          Delineating the mechanism(s) of cell cycle arrest and selectivity of the digitoxin and 
analogs towards cancer cells has several advantages. First, it will increase our 
understanding how digitoxin and analog cause G2/M phase arrest in cancer cells. 
Secondly, it will help identify novel p53-independent therapeutic target(s) to mediate 
cancer cell death. Since many cancer types develop resistance to chemotherapy by 
reducing p53 expression and signaling [114-124], identifying p53-independent therapeutic 
target(s) will contribute to developing new and more effective chemotherapeutic 
alternatives for cancer by circumventing p53 related resistance mechanisms. Also, 
detailing how digitoxin and D6-MA inhibit survivin expression in cancer cells will improve 
our understanding of how digitoxin and analog cause G2/M phase arrest and apoptosis. 
 
 20 
Additionally, understanding how digitoxin and D6-MA inhibit survivin and p53 expression 
in cancer cells would show whether the compounds induce mitotic catastrophe, and if so, 
how. Answering these questions will escalate our understanding of the antineoplastic 
mechanism of CGs at therapeutically relevant concentrations in cancer cells, thus 
opening new and more effective chemotherapeutic alternatives. 
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C H A P T E R  2  
 
DIGITOXIN AND A SYNTHETIC MONOSACCHARIDE ANALOG INHIBIT CELL 
VIABILITY IN LUNG CANCER CELLS 
 
ABSTRACT 
          Mechanisms of digitoxin-inhibited cell growth and induced apoptosis in human non-
small cell lung cancer (NCI-H460) cells remain unclear. Understanding how digitoxin or 
derivate analogs induce their cytotoxic effect below therapeutically relevant 
concentrations will help in designing and developing novel, safer and more effective anti-
cancer drugs. In this chapter, NCI-H460 cells were treated with digitoxin and a synthetic 
analog D6-MA to determine their anti-cancer activity. Different concentrations of digitoxin 
and D6-MA were used and the subsequent changes in cell morphology, viability, cell 
cycle, and protein expressions were determined. Digitoxin and D6-MA induced dose-
dependent apoptotic morphologic changes in NCI-H460 cells via caspase9 cleavage, with 
D6-MA possessing 5-fold greater potency than digitoxin. In comparison, non-tumorigenic 
immortalized bronchial and small airway epithelial cells displayed significantly less 
apoptotic sensitivity compared to NCI-H460 cells suggesting that both digitoxin and D6-
MA were selective for NSCLC. Furthermore, NCI-H460 cells arrested in G2/M phase 
following digitoxin and D6-MA treatment. Post-treatment evaluation of key G2/M 
checkpoint regulatory proteins identified down-regulation of cyclinB1/cdc2 complex and 
survivin. Additionally, Chk1/2 and p53 related proteins experienced down-regulation 
suggesting a p53-independent cell cycle arrest mechanism. In summary, digitoxin and 
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D6-MA exert anti-cancer effects on NCI-H460 cells through apoptosis or cell cycle arrest, 
with D6-MA showing at least 5-fold greater potency relative to digitoxin. 
 
INTRODUCTION 
          Appropriate cell cycle progression is crucial for cell viability [1, 2]. Cardiac 
glycosides (CGs) are a class of natural products known for their cardiotonic and 
antineoplastic effects [3]. In vitro studies on CG pharmacodynamics showed apoptosis, 
autophagy, and cell cycle arrest; however, such effects were selective against tumor cells 
when compared to normal cells [3-6]. Digitoxin, a clinically approved CG for heart failure 
has shown anti-cancer effect in several types of cancer [6]. For instance, Stenkvist et al. 
(1982) found that breast cancer patients on digitoxin regiment (20 nM – 33 nM) displayed 
improved outcomes than untreated patients [7, 8]. Digitoxin induces apoptosis and inhibits 
cancer cell growth by binding to the Na+/K+ATPase pump [3, 6]. Digitoxin-bound 
Na+/K+ATPase activates tyrosine kinase Src, PI3K, phospholipase C and Ras/MAPK 
pathways which leads to antiproliferative downstream effects related to cell growth and 
apoptosis [3, 9]. Given that the integrated sugars give the unique biological function of 
CGs [10-12], digitoxin provides an excellent model to efficiently modify its carbohydrate 
moiety and assess the biological impact of novel synthetic derivatives using cellular-
based experiments. Therefore, synthesis of CG derivatives has become a potential 
approach for developing safer and more effective anti-neoplastic drugs. 
          Previous studies showed that modifying the glycosidic linkage or the 
oligosaccharide moiety of digitoxin could significantly enhance its anti-neoplastic activity 
[10-12]. In other studies, Wang et al. (2010) synthesized and compared stereochemistry 
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structure/activity relationships of the carbohydrate moiety of several digitoxin 
monosaccharide analogs based on a 60 cancer cell line NCI screening for lethal and 
growth inhibitory effects. This screening showed that non-small cell lung cancer (NSCLC) 
cells were more sensitive to digitoxin and its analogs than many other cancer cell lines 
being tested [10, 13]. Additionally, three monosaccharide analogues, namely β-
Ddigitoxose, α-L-rhamnose and α-L amicetose showed at least a 5-fold increase in 
potency to induce apoptosis and growth inhibition in NSCLC [13-15]. However, these 
studies failed to identify the mechanisms mediating the anti-neoplastic effects of digitoxin 
or its synthetic analogs in cancer cells at/or below therapeutically relevant concentrations. 
Understanding the cytotoxic mechanism of digitoxin and its analogs in NSCLC will help in 
designing and developing safer and more effective CG-based anti-cancer therapies. 
          Based on the sensitivity to digitoxin and its analogs [13], and increased resistance 
to chemotherapy [16], NCI-H460 cells were chosen as a NSCLC model in this study. The 
cytotoxic mechanism of digitoxin and α-L-rhamnose digitoxin analog (namely D6-MA) 
were examined below therapeutically relevant concentrations. We hypothesized that 
exposure of NCI-H460 cells to therapeutically relevant doses of digitoxin and D6-MA 
would decrease cell viability due to G2/M arrest and induce apoptosis, with greater 
potency for D6-MA. By comparing cytotoxic mechanisms of digitoxin to D6-MA, we aimed 
to demonstrate that improved anticancer activity can be obtained by sugar-based 




MATERIALS AND METHODS 
Reagents and chemicals 
          Digitoxin was purchased from Sigma Chemicals (St. Louis, MO). Hoechst 
33342, RNase, and propidium iodide (PI) were purchased from Molecular Probes 
(Eugene, OR). MTT cell viability assay kit, Triton X-100, sodium dodecyl sulfate (SDS), 
Tris-HCl, EDTA, NaCl, and Complete Mini cocktail protease inhibitors were purchased 
from Roche Applied Science (Indianapolis, IN). BCA assay kit was purchased from 
Thermo Scientific (Rockford, IL). Cdc2 antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). All other primary and horseradish peroxidase 
conjugated secondary antibodies were purchased from Cell Signaling (Boston, MA). 
Acrylamide/Bis solution was purchased from Bio-Rad Laboratories (Hercules, CA). The 
iBlot® dry blotting and transferring system, PVDF transfer membranes, Countess 
automated cell counter, Countess cell counting chamber slides, and trypan blue stain 
0.4% were purchased from Invitrogen (Carlsbad, CA). High Throughput Colorimetric 
ATPase Assay kit was purchased from Innova Biosciences Ltd. (Babraham, Cambridge, 
UK). 
             Small airway cell basal medium (SABM), SAGM SingleQuots supplementation, 
and Cabrex medium were purchased from Lonza (Walkersville, MD). Purified Na+/K+ 
adenosine 5′-triphosphatase (ATPase) isolated from porcine cerebral cortex, and all other 
chemicals and reagents (including ethanol, isopropanol, Tween 20, Tris-HCl, DMEM 





Synthesis of D6-MA 
          D6-MA, an α-L-rhamnose monosaccharide analog of digitoxin, was synthesized 
from digitoxin based on a previously described method [12, 13]. Briefly, digitoxin was first 
subjected to acid hydrolysis to cleave off the trisaccharide moiety and generate free 
aglycone moiety, digitoxigenin (FIGURE 1A). The monosaccharide moiety was then 
synthesized from α -L-pyranose generated from acetyl furan by asymmetric reduction and 
oxidative rearrangement followed by tert-butoxycarbonyl (BOC) protection of the amino 
group. Subsequently, α -L-pyranose was conjugated with the digitoxigenin moiety via 
palladium-catalyzed glycosylation. The resulting digitoxin-α-L-pyranose was subjected to 
Luche reduction to generate digitoxin-α-L-rhamnoside. 
 
Cell culture 
          Human NSCLC cells (NCI-H460) and non-tumorigenic human bronchial epithelial 
cells (BEAS-2B) were purchased from American Type Culture Collection (ATCC, 
Manassas, VA). Dr. Tom Hei generously provided immortalized small airway epithelial 
cells (hTERT SAEC) cells. The hTERT SAEC cells were developed and authenticated by 
the ectopic expression of human telomerase reverse transcriptase (hTERT) in normal 
human small airway epithelial cells according to the procedure previously described [17]. 
Primary human respiratory epithelial cells (pSAEC), isolated from the small airway of a 
normal human donor (Lonza, Walkersville, MD), were also examined. pSAEC were 
cultured following manufacturer’s directions. Electron microscopy and cytokeratin 8 and 
18 immunostaining were used to verify the phenotype of the cells. pSAEC were identified 
as type I and type II lung epithelial cells with a normal diploid human male karyotype. 
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Cells of at least 90% purity and 80% viability from a single lot were used for all 
experiments. All cell lines were tested for Mycoplasma contamination using Hoechst 
fluorescence staining. Briefly, cells were seeded overnight in a 12 well plate at 1×105 
cells/ml, stained with 10 mg/ml of Hoechst 3342 for 30 minutes and analyzed for the 
presence of foreign or Mycoplasma nuclear material. No Mycoplasma was detected in 
any of the cell lines tested. 
          NCI-H460 cells were cultured in RPMI 1640 medium supplemented with 10% 
bovine fetal serum (FBS), 2 mM L-glutamine and 100-units/ml penicillin/streptomycin. 
BEAS-2B cells were cultured in DMEM medium supplemented with 5% bovine fetal 
serum (FBS), 2 mM L-glutamine and 100-units/ml penicillin/streptomycin. hTERT SAEC 
cells were cultured in SABM medium supplemented with 1% bovine serum albumin and 
SAGM SingleQuots growth factors. Cells were maintained in culture in a humid 
atmosphere containing 5% CO2 at 37ºC. All experiments with NCI-H460 and BEAS-2B 
cells were performed in medium enriched with 1% FBS serum, 2 mM L-glutamine and 
100-units/ml penicillin/streptomycin. 1% FBS was used due to existing concerns about 
digitoxin binding to serum proteins [18, 19].  
 
Cell viability tests with MTT assay 
          Cells were seeded overnight in 96 well plates at a concentration of 1×104 cells/well, 
and then treated for 48 h with a log10 scale dilution series of either digitoxin or D6-MA 
dissolved in sterile filtered DMSO. Subsequently, 10 ml of 5 mg/ml MTT reagent was 
added to each well and then the wells were incubated for 4 h at 37 °C. Isopropanol 
acidified with 0.04 N HCl was used to dissolve converted dye. Absorbance at 570 nm was 
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measured using an Automated Microplate Reader ELx800 (BioTek, Winooski, VT). Each 
experiment was conducted 4 times with 4 replicate wells per concentration. 
 
Trypan blue exclusion assay 
          NCI-H460 cells were seeded overnight in 60 mm2 dishes at 5×105 cell/dish, and 
subsequently treated with 10 nM of either digitoxin or D6-MA for 24 h, 48 h and 72 h. 
After treatment, cells were collected, stained with 0.4% trypan blue, and counted using a 
Countess automated cell counter. 
 
Na+/K+ATPase activity assay 
          Na+/K+ATPase activity assay for release of inorganic phosphate was performed on 
Na+/K+ATPase isolated from porcine cerebral cortex following exposure to each 
compound according to the manufacturer’s protocol. Briefly, serial dilutions of each 
compound were prepared in a buffer containing 50 mM Tris, 25 mM MgCl2, 0.5 mM ATP, 
130 mM NaCl, and 20 mM KCl at pH 7.5, then plated in a 96 well plate in triplicate. 
Subsequently, diluted Na+/K+ATPase was added to each well and the reaction allowed to 
proceed for 15 minutes. The reaction was stopped with Pi ColorLock Gold for 30 minutes, 
and then the absorbance of each well was determined at 595 nm. 
 
Apoptosis assay 
          Cells were seeded overnight in 12 or 24 well plates at a concentration of 1×105 
cell/ml and subsequently treated with different concentrations of either digitoxin or D6-MA 
for 24 h. After treatment, cells were incubated with 10 mg/ml of Hoechst 33342 for 30 
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minutes and analyzed for apoptosis by scoring the percentage of cells having intensely 
condensed chromatin and/or fragmented nuclei using fluorescence microscopy (Leica 
Microsystems, Bannockburn, IL). Approximately 1,000 nuclei from ten random fields were 
analyzed for each sample. The apoptotic index was calculated as the percentage of cells 
with apoptotic nuclei over total number of cells. 
 
Cell cycle analysis 
          NCI-H460 cells were seeded in 60 mm2 cell culture dishes at a concentration of 
5×105 cells/dish, starved overnight in serum-free media, and then treated with 1, 5, 10, 
and 20 nM of either digitoxin or D6-MA for 48 h. Treated cells were then trypsinized, 
collected, washed with PBS and fixed in 70% ethanol at 4oC overnight. Subsequently, 
cells were washed with PBS and stained with propidium iodide containing 0.05% RNase. 
For cell cycle analysis, the DNA content was determined using a FACScan laser flow 
cytometer (FACSCalibur; Becton Dickinson, San Jose, CA). Data were analyzed using 
MODFIT software (Verity Software House, Topsham, ME). Experiments were repeated 4 
times to conduct statistical analysis. 
 
Western blot analysis 
          Cells were seeded in 60 mm2 cell culture dishes at a concentration of 1×106 
cell/plate, starved overnight, and then treated with 5 to 50 nM of either digitoxin or D6-MA 
for 24 h. After treatment, cells were collected and lysed for 30 minutes on ice in lysis 
buffer containing 2% Triton X-100, 1% sodium dodecyl sulfate (SDS), 100 mM NaCl, 10 
mM, Tris-HCl (pH 7.5), 1 mM EDTA, and Complete Mini cocktail protease inhibitors. 
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Insoluble debris was pelleted by centrifugation at 4°C and 6800 g for 15 minutes. 
Subsequently, the supernatant was collected and used to determine protein content using 
BCA assay. Briefly, diluted supernatant samples and bovine serum albumin standards 
were plated in duplicate to a 96 well plate. Working reagent (1000 µL) was prepared by 
mixing 50 parts of reagent A (1000 µL) with 1 part of reagent B (20 µL), added to each 
well (200 µL each), and incubated at 37oC for 30 minutes with 2 µL of each protein 
sample. Absorbance of each well was measured at 562 nm with a Varioskan 
spectrophotometer (Thermo, Waltham, MA). BSA protein standard curves were used as 
standards to determine sample protein content. 
          Samples were next separated on 12% SDS-PAGE and transferred to PVDF 
membranes using the iBlot® Dry Blotting System. Membranes were blocked in 5% skim 
milk in TBST (25 mM Tris–HCl, pH 7.4, 125 mM NaCl, 0.1% Tween 20) for 1 h, and 
subsequently incubated with appropriate primary antibodies at 4°C overnight. Membranes 
were washed three times for 10 minutes each with TBST and then incubated with 
horseradish peroxidase-conjugated secondary antibodies for 2 h at room temperature. 
The immune complexes formed were detected by chemiluminescence (Supersignal West 
Pico; Pierce, Rockford, IL). Band quantification via densitometry was performed using 
ImageJ software version 10.2. 
 
Statistical analysis 
          All results are presented as mean ± standard deviation. For cell viability, ATPase 
activity and apoptosis assays, dose-response curves and concentrations that caused 
50% effect (i.e. IC50) were calculated for both digitoxin and D6-MA in all the cell lines 
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tested using non-linear regression analysis in GraphPad Prism 5.0 (San Diego, CA). Two-
way analysis of variance (ANOVA) and unpaired two-tailed Student’s t-test with α = 0.05 
were performed to compare the effect of compounds and administered dose on cell 
viability, apoptosis and quantified protein expression data. Interactions between variables 
were tested for and were used as an error term in case they were significant. Post-hoc 
Tukey-Kramer HSD tests were conducted on significant ANOVA results. Results were 
considered significant when p < 0.05. 
 
RESULTS 
D6-MA causes inhibition of NCI-H460 cell viability and Na+/K+ATPase enzyme activity 
          D6-MA, a digitoxin analog, was prepared by subjecting digitoxin-α-L-pyranoside to 
post-glycosylation modification (FIGURE 1A) as previously described [13, 15]. To 
evaluate whether D6-MA exhibits greater potency than digitoxin to inhibit NCI-H460 cell 
viability, we performed colorimetric MTT and trypan blue exclusion assays. Non-linear 
regression analysis (FIGURE 1B) showed that D6-MA exhibited about 4-fold greater 
potency (IC50= 12.0 nM) than digitoxin (IC50 = 49.4 nM) while Student’s t-test detected 
digitoxin’s and D6-MA’s inhibition lowest observed effective concentration (LOEC) at 10 
nM and 1 nM (p<0.001) respectively. Additionally, two-way ANOVA test showed that 
while both compounds significantly inhibited NCI-H460 cell viability in a time dependent 
manner, D6-MA was significantly more potent than digitoxin (FIGURE 1C; F = 18.11, p 
<0.0001). Next, we tested whether the compounds inhibit Na+/K+ATPase enzyme activity. 
Non-linear regression analysis showed that D6-MA is more potent (IC50= 1.1 µM) than 




FIGURE 1: Digitoxin and D6-MA inhibit NCI-H460 cell viability in a dose dependent 
manner. (A) α-L-rhamnose monosaccharide analog (D6-MA) was synthesized from 
digitoxin. (B) Dose-response curve showing a 4-fold difference in potency between 
digitoxin and D6-MA for inhibition of cell viability generated by colorimetric MTT cell 
viability assay. (C) Time-response inhibition of cell proliferation after treatment with 10 nM 
of either digitoxin or D6-MA; (*) indicates significantly different from control, (†) indicates 
significantly different from digitoxin. (D) Dose-response inhibition of Na+/K+ATPase 
activity. 
 
D6-MA induces apoptosis in NCI-H460 cells 
          Previous studies attributed the anti-neoplastic effects of CG to their capacity to 
induce apoptosis [3]. To investigate whether D6-MA is more potent than digitoxin in 
inducing apoptosis, we exposed NCI-H460 cells to each of the compounds and used 
Hoechst 33342 DNA fragmentation assay to evaluate the apoptotic effects. Non-linear 
regression analysis showed that the percentage of NCI-H460 cells displaying apoptotic 
 
 47 
nuclei was both dose and compound dependent (FIGURE 2A and 2B), with D6-MA 
displaying about 5-fold greater potency (IC50 = 10 nM) when compared to digitoxin (IC50= 
48 nM). 
 
FIGURE 2: Digitoxin and D6-MA induce NCI-H460 cell apoptosis in a dose dependent 
manner. (A) Dose-response induced apoptosis. (B) Hoechst staining and fluorescence 
microscopy images of NCI-H460 cells. Arrows point to apoptotic cells. 
 
D6-MA exhibits selective cytotoxicity to NSCLC cells  
          Anti-cancer drugs ought to be selectively toxic toward cancer cells and not normal 
cells. To test whether digitoxin and D6-MA are selectively toxic to NSCLC cells, we 
exposed primary small airway epithelial cells (pSAEC), immortalized non-tumorigenic 
human small airway epithelial cells (hTERT SAEC), and immortalized non-tumorigenic 
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human bronchial epithelial cells (BEAS-2B) to digitoxin and D6-MA, and used Hoechst 
33342 DNA fragmentation assay to evaluate apoptosis in these cell lines. Interestingly, 
non-linear regression analysis showed that treated hTERT SAEC and BEAS-2B cells had 
significantly less sensitivity to apoptosis for either of the compounds when compared to 
NCI-H460 cells (FIGURE 3A and B).  
 
 
FIGURE 3: The apoptotic effect of digitoxin and D6-MA is selective to non-small cell lung 
cancer cells. (A) Digitoxin dose-response in hTERT SAEC, BEAS-2B, and NCIH460 cells. 
(B) D6-MA dose-response in hTERT SAEC, BEAS-2B, and NCI-H460 cells. (C) Non-
tumorigenic hTERT SAEC cells and BEAS-2B cells have higher IC50 values than NCI-
H460 cells. Error bars represent IC50 values at 95% confidence intervals. (D) Primary 
SAEC cells, non-tumorigenic hTERT SAEC cells, and BEAS-2B cells are less sensitive to 
apoptosis for either digitoxin (50 nM) or D6-MA (10 nM). Error bars represent standard 
deviation; (*) indicates significantly different from untreated cells. 
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          To validate this finding, an apoptosis assay with set doses of digitoxin and D6-MA 
on all four cell lines was conducted. Two-way ANOVA showed a significant difference 
between cell line sensitivity (FIGURE 3C; F=91.84, p<0.0001) while no difference existed 
between the compounds with dosing placed at a 5-fold interval. Specifically, NCI-H460 
and BEAS-2B cells showed greater sensitivity to each compound while both SAEC cell 
lines displayed minimal sensitivity. In addition, D6-MA exhibited a 4-fold greater potency 
than digitoxin to induce apoptosis regardless of cell type (FIGURE 3D). 
 
D6-MA induces expression of cytochrome c and extensive caspase9 cleavage 
          Previous studies have shown that sequential activation of caspases and increased 
cytochrome c expression play a central role in the execution phase of apoptosis [20]. 
Specifically, caspase8 and caspase9 mediate the extrinsic (death ligand) and intrinsic 
(mitochondrial) apoptotic pathways, respectively. Studies have also shown that caspase3 
interacts with both caspase8 and -9 and experiences activation in both apoptotic signaling 
pathways [20]. With persistent apoptotic stimulus, increased cytochrome c is released 
from mitochondria into the cytoplasm, recruits pro-caspase 9 and APAF1 and forms the 





FIGURE 4: Western blot analysis show changes in caspase9, 8, and 3. (A) Digitoxin and 
D6-MA induced differential cleavage of caspase9. Digitoxin caused pro-caspase 3 to drop 
at 50 nM, while D6-MA caused pro-caspase 3 to drop at 20 nM. (B) Quantification of 
cleaved caspase9 blots shows fold change in cleavage following treatment. (C) 
Quantification of cleaved caspase8 blots shows fold change in cleavage following 
treatment. (D) Quantification of pro-caspase 3 blots shows decrease in quantity following 
treatment; (*) indicates significantly different from control, (†) indicates significantly 
different from digitoxin. 
 
           To examine which apoptotic pathway predominates in NCI-H460 cells exposed to 
digitoxin or D6-MA, we performed Western blot analysis for cytochrome c and caspase 
cleavage respectively. Based on β-actin expression (used as control), two-way ANOVA 
with subsequent post-hoc tests showed that D6-MA exhibited greater potency than 
digitoxin in inducing substantial caspase9 cleavage (FIGURE 4A, and 4B; F=28.78, 
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p<0.0001). Pro-caspase 3 experienced a significant drop in expression (FIGURE 4A, and 
4C; F=7.19, p<0.0001) while caspase8 displayed slight cleavage following digitoxin and 
D6-MA treatment (FIGURE 4A, and 4D; F=16.06, p=0.066). 
 
FIGURE 5: Western blot analysis shows changes in cytochrome c expression. (A) 
Digitoxin and D6-MA induce cytochrome c expression in a dose dependent manner. (B) 
D6-MA is more potent than digitoxin in inducing cytochrome c expression (F=25.51, 
p<0.001). Quantification of cytochrome c blots shows increased expression following 
treatment (*p<0.05 compared 0 nM, †p<0.05 compared to digitoxin treatment). 
 
           Additionally, two-way ANOVA and post-hoc testing showed that D6-MA was more 
potent than digitoxin in inducing cytochrome c expression (FIGURE 5A) at 10 nM while at 




Digitoxin and D6-MA induce G2/M phase arrest 
          Previous research suggested that cell cycle arrest causes apoptosis or loss of cell 
viability [2, 21]. To investigate whether digitoxin or D6-MA induces cell cycle arrest, we 
exposed NCI-H460 cells to different doses of either digitoxin or D6-MA for 48 h. Using 
two-way ANOVA our results showed that digitoxin and D6-MA significantly increased the 
percentage of cells in sub-G1 phase in a dose dependent manner (FIGURE 6A and 
FIGURE 6B; F = 16.1, p <0.0001).  
 
FIGURE 6: Digitoxin and D6-MA induce G2/M arrest in NCI-H460 cells. (A) Digitoxin and 
D6-MA induced an increase in the G2/M and sub-G1 cell populations. (B) Digitoxin and 
D6-MA pushed cells into sub-G1 phase. (C) Digitoxin and D6-MA induced significant 
G2/M phase arrest compared to controls; (*) indicates significantly different from control, 




Additionally, D6-MA was significantly more potent than digitoxin at 20 nM (FIGURE 6B; 
p=0.0071). Both compounds induced G2/M arrest and in a dose-dependent manner 
(FIGURE 6A and FIGURE 6C; p = 0.0099). D6-MA’s LOEC for inducing G2/M phase 
arrest was at 1 nM, while digitoxin showed comparable effect at 5 nM. Moreover, digitoxin 
increased G2/M phase arrest in a dose dependent manner, while D6-MA G2/M phase 
arrest peaked between 1 and 5 nM and then decreased to control levels at 20 nM.  
                Our results suggest that the drop in the percentage of D6-MA-treated cells in 
G2/M phase coincide with a significant increase of cells in sub-G1 phase. 
 
Digitoxin and D6-MA induce down-regulation of cyclin B, cdc2, and survivin 
           Inducing G2/M phase arrest usually occurs following an alteration in the signaling 
pathways that control cell progression through G2/M phase [22]. Since our results 
showed that the percentage of cells in G2/M phase increased upon exposure to digitoxin 
and D6-MA, we further investigated how digitoxin and D6-MA induce G2/M phase arrest. 
Specifically, we examined the expression of key molecular drivers of G2/M phase, namely 
cyclinB1, cdc2, and survivin, using Western blot analysis. Cdc2 requires both cdc2 and 
cyclinB1 in the complex form for adequate activity. CyclinB1/cdc2 complex is known to 
catalyze the chromatin condensation as well as nuclear envelope breakdown during 
mitosis, thus performing a key and rate limiting function in the cell transition from G2 to M 
phase [22]. Survivin promotes mitosis by activating the chromosomal passenger complex 
[23]. Moreover, the phosphorylation of survivin by cyclinB1/cdc2 complex facilitates the 
association of survivin/caspase9, which inhibits caspase9 activity [24]. Two-way ANOVA 
testing revealed that D6-MA was significantly more potent than digitoxin in inducing dose-
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dependent down regulation of cyclinB1, cdc2, and survivin (FIGURE 7A-E; F= 29.06, 6.8, 
and 25.43; p<0.0001, 0.0036, and 0.0001 respectively) based on β-actin and GAPDH 
expression.).  
 
FIGURE 7: Western blot analysis show decreased expression of cyclinB1, cdc2, and 
survivin. (A) Digitoxin and D6-MA inhibited cyclinB1 and cdc2 expression in a dose 
dependent manner. (B) Digitoxin and D6-MA inhibited survivin expression in a dose 
dependent manner. (C) D6-MA is more potent than digitoxin in inhibiting cyclinB1 
expression (F=29.06, p<0.001). Quantification of cyclinB1 blots shows decreased 
expression following treatment (*p<0.05 compared 0 nM, †p<0.05 compared to respective 
digitoxin treatment). (D) D6-MA is more potent than digitoxin in inhibiting cdc2 expression 
(F=6.805, p=0.0036). Quantification of cdc2 blots shows decreased expression following 
treatment (*p<0.05 compared 0 nM, †p<0.05 compared to respective digitoxin treatment). 
(E) D6-MA is more potent than digitoxin in inhibiting survivin expression (F=25.43, 
p<0.001). Quantification of survivin blots shows decreased expression following treatment 





D6-MA’s LOEC for reducing expression of both cyclin B and cdc2 was 5 nM while 
digitoxin showed similar effect at 10 nM (FIGURE 7C and D). Both compounds exhibited 
reduced survivin expression LOEC at 5 nM (FIGURE 7E). Interestingly, the doses that 
resulted in reduced expression of each protein correlated with the observed arrest in 
G2/M phase; moreover, this was dependent on compound treatment, thus implicating 
these proteins in cell cycle arrest signaling. 
 
Digitoxin and D6-MA-mediated G2/M phase arrest does not correlate with up-regulation 
of p53-related signaling protein or Chk1/2 
          We further aimed to identify the signaling pathways that mediate G2/M phase arrest 
following exposure to digitoxin or D6-MA. For this we examined the key upstream 
regulatory pathways of the cyclinB1/cdc2 complex. Since p53 functions as a key 
coordinator of cell cycle check point activity and as an effective promoter of apoptosis [22, 
25], we also examined p53-related signaling including p53, p21, and p27 [25]. Our results 
showed that while digitoxin significantly inhibited the expression of p53, p21, and p27 at 
concentrations between 5 to 20 nM, D6-MA was significantly more potent in inducing 
down-regulation of p53, p21, and p27 (FIGURE 8A). Specifically, two-way ANOVA and 
post-hoc testing confirmed that p53, p21 and p27 expression was compound and dose 






FIGURE 8: Western blot analysis show decreased expression of p53, p21, and p27. (A) 
Digitoxin and D6-MA down-regulated p53, p21, and p27 in a dose dependent manner. (B) 
D6-MA is more potent than digitoxin in inhibiting p53 expression (F=52.89, p<0.001). 
Quantification of p53 blots shows decreased expression following treatment (*p<0.05 
compared 0 nM, †p<0.05 compared to respective digitoxin treatment). (C) D6-MA is more 
potent than digitoxin in inhibiting p21 expression (F=4.23, p<0.001). Quantification of p21 
blots shows decreased expression following treatment (*p<0.05 compared 0 nM, †p<0.05 
compared to respective digitoxin treatment). (D) D6-MA is more potent than digitoxin in 
inhibiting p27 expression (F=2.06, p=0.008). Quantification of p27 blots shows decreased 
expression following treatment (*p<0.05 compared 0 nM, †p<0.05 compared to respective 
digitoxin treatment). 
 
              We also examined whether checkpoint kinase 1 and 2 (Chk1/2) up-regulation 
contributed to G2/M phase arrest signaling. Chk1/2 is involved in DNA damage response 
and in normal cell cycle progression by controlling cell cycle checkpoints [26-28]. Our 
results and two-way ANOVA analysis showed that digitoxin and D6-MA induced inhibition 
of Chk1 and Chk 2 expression and was dose-dependent (FIGURE 9A-C; F = 36.11 and 
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7.982; p<0.001 and 0.002 respectively). Notably, Chk1 experienced a 2-fold decrease in 
expression while Chk2 exhibited a less substantial decrease. Reduced expression of both 
proteins correlated with similar trends observed with cyclin B and cdc2. 
 
FIGURE 9: Western blot analysis show decreased expression of Chk1 and Chk2. (A) 
Digitoxin and D6-MA down-regulated Chk1 and Chk2 in a dose dependent manner. (B) 
D6-MA is more potent than digitoxin in inhibiting Chk1 expression (F=10.17, p<0.001). 
Quantification of Chk1 blots shows decreased expression following treatment (*p<0.05 
compared 0 nM, †p<0.05 compared to respective digitoxin treatment). (C) D6-MA is more 
potent than digitoxin in inhibiting Chk2 expression (F=7.982, p<0.001). Quantification of 
Chk2 blots shows decreased expression following treatment (*p<0.05 compared 0 nM, 
†p<0.05 compared to respective digitoxin treatment). 
 
DISCUSSION 
          Our study aimed to evaluate and compare the cytotoxic potency of digitoxin and 
D6-MA in NCI-H460 cells in order to derive the mechanisms and signaling pathways 
responsible for cell cycle arrest. Such studies could lead to feasible, reliable and more 
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potent drug therapies, which exhibit potent anti-cancer effects at safe and therapeutically 
relevant doses. Our results showed that digitoxin and D6-MA modulates one or several 
signaling pathways controlling cell cycle progression, cell proliferation, and apoptosis. 
          Cardiac glycosides (CGs) are known to mediate their cellular effects by inhibiting 
the Na+/K+ATPase activity, by affecting ion homeostasis at high doses and activating the 
ATPase signalosome at low doses [3, 29]. Our studies showed that D6-MA is more potent 
than digitoxin at inhibiting Na+/K+ATPase activity. Interestingly, concentrations of digitoxin 
and D6-MA that inhibited Na+/K+ATPase activity were more than 10-fold greater than their 
cytotoxic concentrations. This result suggests that Na+/K+ ATPase inhibition by either 
digitoxin or D6-MA does not account for drug or analog cytotoxic effects, thus leaving the 
possibility for signalosome activation. 
          We hypothesized that the apoptotic effect of digitoxin and D6-MA are selective to 
NSCLC cells. To test this hypothesis, we performed Hoechst apoptosis assay on primary 
human lung epithelial cells and non-tumorigenic human lung epithelial cells treated with 
each compound. Our results showed that D6-MA caused increased apoptosis when 
compared to digitoxin in all the cell lines being tested. Moreover, digitoxin and D6-MA 
showed higher IC50 values in non-tumorigenic lung epithelial cells than in NSCLC cells. 
Thus, this confirmed that primary human lung epithelial cells and non-tumorigenic human 
lung epithelial cells are significantly less sensitive to digitoxin and D6-MA when compared 
to NCI-H460 cells. 
          We further hypothesized that for both digitoxin and D6-MA, apoptosis is mediated 
through the mitochondrial pathway. Mitochondrial pathway involvement leads to 
cytochrome c release and association with pro-caspase 9 and APAF-1 respectively [20]. 
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Such association leads to caspase9 and caspase3 activation and induced cell apoptosis 
[20]. To test this hypothesis, we performed Western blot analysis of NCI-H460 cells 
exposed to digitoxin and D6-MA, respectively. Our results showed that D6-MA was more 
potent than digitoxin in inducing cytochrome c expression and cleavage of caspase9, 
while for pro-caspase 3 there was a drop in expression and only slight differential 
cleavage for caspase8. In addition, increased cytochrome c expression suggests that 
H460 cells retained their ability to synthesize protein, which contrasts previous claims that 
CG induced cytotoxicity is due to general inhibition of protein synthesis [30]. 
          We further investigated cyclinB1 and cdc2 regulation; cyclinB1 and cdc2 form 
cyclinB1/cdc2 complex that is crucial for progression of cells through G2/M phase, 
protects mitotic cells from apoptosis, and maintains cancer cell viability [22, 31, 32]. We 
showed down-regulation of cyclinB1 and cdc2 by both digitoxin and D6-MA, with D6-MA 
exhibiting greater potency in reducing cell viability.  
          We also tested whether survivin, a protein that promotes mitosis by activating the 
chromosomal passenger complex [23] is involved in the reduced NCI-H460 cell viability. 
Our results showed that digitoxin and D6-MA induced survivin down-regulation at sub-
therapeutic concentrations, with D6-MA being significantly more potent than digitoxin. 
Such down-regulation further explains the observed G2/M phase arrest and points to 
survivin as being a viable target for digitoxin or D6-MA mediated anti-neoplastic activity in 
NCI-H460 cells. 
          Our results provide further support that cytotoxic effects of CGs are independent of 
p53 status. Digitoxin’s ability to down-regulate p53, even though is first demonstrated in 
this study, is supported by previous reports employing other CGs (such as ouabain and 
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digoxin) in both breast and lung cancer cells [33, 34]. For instance, p53 null and p53 wild 
type lung cancer cells were previously shown to exhibit equal cell death when exposed to 
CGs [34]. In addition, we also report for the first time on the down-regulation of p21 and 
p27 by digitoxin and D6-MA. Several studies suggested that p21 possesses oncogenic 
properties in promoting mitosis and cell migration [35-37]. In contrast to our findings, p21 
up-regulation in breast cancer cells following ouabain exposure was reported [33]. p21 
down-regulation possibly explains the reduced NCI-H460 cell viability following digitoxin 
and D6-MA exposure. 
          We also studied Chk1/2 expression to further explain the reduced cell viability 
associated with G2/M arrest. Chk1/2 is known to mediate cell cycle arrest following DNA 
damage or stress response [27, 28, 38]. Abrogating cell cycle checkpoints by 
chemotherapeutic agents that specifically target Chk1/2 was shown to be an effective 
chemotherapeutic alternative for several types of cancer [27, 28, 38]. We are first to show 
that digitoxin and D6-MA inhibit Chk1/2 expression at sub-therapeutic concentrations in 
NCI-H460 cells, with the D6-MA being more potent than digitoxin. These results indicate 
that following digitoxin or D6-MA treatment neither G2/M phase arrest, nor down-
regulation of cyclinB1 and cdc2 is mediated by the up-regulation of Chk1/2. However, 
down-regulation of Chk1/2 following treatment with digitoxin or D6-MA at sub-therapeutic 
concentrations can explain the reduced cell viability found in our studies. 
          The results presented herein further advance our understanding of the selective 
anti-neoplastic mechanism of sub-therapeutic digitoxin concentrations towards NSCLC 
cancer cells. In addition, enhanced and selective anti-neoplastic activity of D6-MA for 
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NSCLC opens new perspectives for more effective chemotherapeutic strategies based on 
artificially synthesized compounds. 
 
CONCLUSIONS 
          This study is the first to focus on determining anti-neoplastic effects of realistic, sub-
therapeutic doses of digitoxin and D6-MA in NCI-H460 cancer cells. We show for the first 
time that sub-therapeutic concentrations of digitoxin and D6-MA induce G2/M phase 
arrest and cyclinB1 and cdc2 down-regulation, with D6-MA exhibiting greater potency 
than digitoxin. Our results also suggest that G2/M phase arrest and down regulation of 
cyclinB1 and cdc2 by digitoxin and D6-MA are not directly controlled by up-regulation of 
p53 signaling or checkpoint kinase signaling. 
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S U M M A R Y  A N D  C O N C L U S I O N  
            Lung cancer cells exhibit a significant sensitivity to digitoxin and its 
monosaccharide analog, indicating that these compounds may be clinically beneficial for 
management and treatment of cancer. Digitoxin and its analog, D6-MA, exhibit a selective 
antineoplastic effect in NSCLC cells at therapeutic concentrations. D6-MA showed 4 to 6 
times greater potency than digitoxin in inhibiting non-small cell lung cancer cells viability. 
Digitoxin and D6-MA do not inhibit Na+/K+ATPase pump at their cytotoxic concentrations, 
indicating that inhibiting the Na+/K+ATPase by digitoxin or D6-MA does not account for 
their anticancer activity. Thus, cardiotoxicity may no longer be a concern for these 
compounds, since the cardiotoxicity mechanism impinges on inhibiting the Na+/K+ATPase 
pump. Additionally, if inhibiting the Na+/K+ATPase pump by digitoxin and D6-MA does not 
account for their cytotoxicity, then manipulating the Na+/K+ATPase signalosome remains 
as the general mechanism for the cellular effects exhibited by digitoxin and D6-MA. 
         Digitoxin and D6-MA induced apoptosis through the mitochondrial pathway as 
confirmed by increased cytochrome c and caspase9 cleavage and activation. D6-MA was 
even more potent than digitoxin in inducing cytochrome c expression and caspase9 
activation and in inhibiting the expression of cyclin B1, cdc2, and survivin. The ability of 
digitoxin and D6-MA to inhibit cyclin B1, cdc2, and survivin explains the ability of the 
compounds to specifically activate caspase9. Additionally, down regulation of cyclin B1, 
cdc2, and survivin contributes to explaining the strong reduction in cell viability induced by 
digitoxin and D6-MA. 
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          Interestingly, however, the cytotoxic effect of digitoxin and D6-MA is independent of 
up regulation of p53 or checkpoint kinase proteins. This indicates that other signaling 
pathways are controlling this cytotoxic effect and so further research is required to 
delineate such mechanisms. Additionally, the ability of digitoxin and D6-MA to inhibit the 
expression of checkpoint kinase proteins further explains their potent cytotoxic activity in 
cancer cells. Such discoveries open up possibilities for new chemotherapeutic 
compounds that specifically target apoptosis in cancer cells at concentrations that are 
non-toxic to normal cells. 
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Professional Pharmacy Practicing License, Ministry of Health and Population, Egypt, 




Bilingual; Fluent English and Arabic  
Teaching and Presentation skills 
Oral Communication Skills 
Capacity and Desire for learning 
Determination  




Western blot analysis 
Optical microscopy 
Confocal and Fluorescence Staining 
Spectrophotometry 




Drug Target Identification / Validation 
Drug Discovery  
Drug Delivery 
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In Vitro Pharmacology 






American Chemical Society (2011-Present) 
Golden Key International Honor Society (2010-Present) 
American Association of Pharmaceutical Scientists (2009-Present) 
American Society of Pharmacology and Experimental Therapeutics (2009-Present) 
Egyptian Student Association of North America (2008-Present) 
Egyptian General Syndicate of Pharmacists (2006-Present) 
 
 
 
 
 
